Emergent BioSolutions (EBS) Cash from Financing Activities (2010 - 2026)
Emergent BioSolutions (EBS) posted Cash from Financing Activities of -$24.4 million for Q2 2026, down 114.04% on a QoQ basis from -$11.4 million in Q1 2026, and down 281.25% year-over-year from $13.5 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Emergent BioSolutions has reported Cash from Financing Activities for 17 years, with the latest figure at -$24.4 million in Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 281.25% year-over-year to -$24.4 million in Q2 2026; TTM through Jun 2026 was -$165.6 million, a 11.25% increase from a year earlier, with the FY2025 full-year figure at -$136.6 million, up 28.11% from the prior year.
- Cash from Financing Activities was -$24.4 million for Q2 2026 at Emergent BioSolutions, down from -$11.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $353.1 million in Q4 2022, with the low at -$486.9 million in Q2 2023.
- Average Cash from Financing Activities over 5 years is -$23.2 million, with a median of -$13.6 million recorded in 2025.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities soared 4686.0% in 2022, then tumbled 22880.0% in 2025.
- Over 5 years, Cash from Financing Activities stood at $353.1 million in 2022, then sank by 98.67% to $4.7 million in 2023, then slumped by 89.36% to $500000.0 in 2024, then sank by 22880.0% to -$113.9 million in 2025, then surged by 78.58% to -$24.4 million in 2026.
- The last three Cash from Financing Activities figures came in at -$24.4 million (Q2 2026), -$11.4 million (Q1 2026), and -$113.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | -3.66 Bn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | -2.63 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | -2.10 Bn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | -6.05 Mn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | 2.42 Bn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | -24.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.40 Mn |
| Mar 31, 2026 | -11.40 Mn |
| Dec 31, 2025 | -113.90 Mn |
| Sep 30, 2025 | -15.90 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Mar 31, 2025 | -400,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | -180.30 Mn |
| Jun 30, 2024 | -50.90 Mn |
| Mar 31, 2024 | 40.70 Mn |
| Dec 31, 2023 | 4.70 Mn |
| Sep 30, 2023 | -43.00 Mn |
| Jun 30, 2023 | -486.90 Mn |
| Mar 31, 2023 | -10.50 Mn |
| Dec 31, 2022 | 353.10 Mn |
| Sep 30, 2022 | 229.30 Mn |
| Jun 30, 2022 | -30.70 Mn |
| Mar 31, 2022 | -70.50 Mn |
| Dec 31, 2021 | -110.00 Mn |
| Sep 30, 2021 | -5.00 Mn |
API Access
Emergent BioSolutions Cash from Financing Activities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-financing-activities", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();